Analysis method for determining five antibacterial agents in dried blood spots through LC-MSMS

The dry blood spot samples were optimized through LC-MS/MS technology, which solved the problems of poor sample stability and large blood collection in the existing TDM methods, and achieved high sensitivity quantitative detection of five antibacterial drugs, suitable for critically ill patients Individualized therapy and pharmacokinetic studies.

CN118937510APending Publication Date: 2024-11-12SHANGHAI TONGJI HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410880544.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing TDM detection methods usually require a large blood sample volume, poor sample stability, making it difficult to achieve individualized monitoring of multi-drug combined treatment for critically ill patients, especially the distribution volume and clearance rate of hydrophilic antibacterial drugs are difficult to accurately determine.

Method used

Detection of meropenem, imipenem, tigecycline, tecolanin and vancomycin by dry blood spots (DBS) samples using LC-MS/MS technology. Sample pretreatment includes spot coating and drying on Whatman cards. , and then add acetonitrile aqueous solution and internal standard working solution, and perform LC-MS/MS analysis after ultrasonic centrifugation. The chromatographic conditions and mass spectrometry conditions are optimized to achieve fast and high-sensitivity quantitative detection.

Benefits of technology

It has achieved high sensitivity quantitative detection of five antibacterial drugs, with small blood collection and high stability. It is suitable for frequent monitoring and individualized treatment of critically ill patients, reducing biohazards, and is suitable for clinical TDM and pharmacokinetic research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937510A_ABST
    Figure CN118937510A_ABST
Patent Text Reader

Abstract

The invention discloses an analysis method for determining five antibacterial drugs in dried blood spots through LC-MSMS, the antibacterial drugs are meropenem, imipenem, tigecycline, teicoplanin and vancomycin, and the analysis method comprises the following steps: step 1, sample pretreatment; step 2, detecting by adopting LC-MS / MS (liquid chromatography-tandem mass spectrometry); wherein the chromatographic conditions are as follows: the chromatographic column is Acquity UPLC BEH C18, 2.1 * 100 mm, 1.7 [mu] m, the column temperature is 30 DEG C, the column temperature is 30 DEG C, and the column temperature is 30 DEG C; a mobile phase A is ultrapure water containing 0.1 v / v% of formic acid; a mobile phase B is acetonitrile; the temperature of a chromatographic column is 45 DEG C; the sample size is 2 [mu] L; the flow velocity of a mobile phase is 0.3 mL / min; the total operation time is 6 minutes; and gradient elution. The analysis method disclosed by the invention is high in sensitivity and can be used for quantitatively detecting the blood concentration of the five antibacterial drugs at the same time; the method is applied to TDM research and pharmacokinetic research of critical patients, the blood sampling amount is only 30 microliters, frequent and repeated blood sampling of the critical patients is friendly, and technical support can be provided for clinical individualized treatment and PK / PD research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antimicrobial drug detection, and in particular to an analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS. Background Art

[0002] In clinical treatment, especially in the treatment of critically ill infected patients, individualized antimicrobial therapy is necessary to help optimally monitor patients and curb bacterial resistance. The dose of antimicrobial drugs should be adjusted according to the drug exposure and the sensitivity of the infected site. PK parameters are affected by a variety of pathophysiological factors or other iatrogenic factors, and the PK / PD targets of antimicrobial drugs are difficult to achieve accurately, especially for hydrophilic antimicrobial drugs (aminoglycosides, β-lactams, glycopeptides, lipopeptides, etc.), whose PK parameters such as distribution volume and clearance are more susceptible to influence. Meropenem, imipenem, tigecycline, teicoplanin, and vancomycin are commonly used antimicrobial drugs in ICUs, belonging to carbapenems, glycylcyclines, and glycopeptides. These five drugs are commonly used antimicrobial drugs in intensive care units to combat Gram-negative and Gram-positive bacterial infections. With the continuous deepening of knowledge on antibiotic pharmacokinetics and pharmacodynamics (PK / PD), antibiotic pharmacokinetics will change in critically ill patients in ICU due to physiological dysfunction and serious and complex conditions. The above factors may lead to suboptimal antibiotic exposure, so it is particularly important to perform TDM testing of antimicrobial drugs in patients with severe infections.

[0003] There are currently deficiencies in the development of TDM methods: 1) Methods are often established using a single drug or a class of drugs as the target analyte, but clinical treatment, especially for critically ill patients, often requires the combined use of multiple drugs; 2) TDM testing is usually performed on serum or plasma samples obtained from venous blood draws, with a single blood draw volume of at least one thousand microliters; 3) Plasma or serum samples are used for TDM of clinical samples, however, it is known that there are problems with sample stability in serum or plasma samples at room temperature, which poses challenges to sample transportation and storage as well as routine therapeutic monitoring of drugs. Summary of the invention

[0004] The object of the present invention is to provide an analytical method for determining five antibacterial drugs in dried blood spots by LC-MSMS in view of the deficiencies in the prior art.

[0005] To achieve the above object, the technical solution adopted by the present invention is:

[0006] Provided is an analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS, wherein the antimicrobial drugs are meropenem, imipenem, tigecycline, teicoplanin and vancomycin, comprising the following steps:

[0007] Step 1, sample pretreatment;

[0008] Step 2, using LC-MS / MS detection;

[0009] The chromatographic conditions are:

[0010] Chromatographic column: Acquity UPLC BEH C18, 2.1×100mm, 1.7μm; Mobile phase A: ultrapure water containing 0.1v / v% formic acid; Mobile phase B: acetonitrile; Column temperature: 45°C; Injection volume: 2μL; Mobile phase flow rate: 0.3mL / min; Total run time: 6 minutes; Gradient elution;

[0011] The mass spectrometry conditions were:

[0012] The ionization mode was positive electrospray ionization, the spray voltage was 3500 V, the ion transfer tube temperature was 350 °C, the vaporization temperature was 400 °C, the sheath gas flow rate was 50, the auxiliary gas flow rate was 15, and the scan gas flow rate was 1.

[0013] Furthermore, the specific procedure of the gradient elution is: 0-1 min, 0-30% B; 1-3 min, 30-98% B; 3-3.5 min, 98% B; 3.51-min, 1% B.

[0014] Furthermore, the specific steps of the sample pretreatment are: cutting whole points from the DBS sample and transferring them to an Eppendorf tube, adding acetonitrile aqueous solution and internal standard working solution, ultrasonicating, centrifuging, and obtaining a supernatant to be tested.

[0015] Furthermore, the DBS sample is prepared by:

[0016] ① For whole blood samples, use a plastic pipette to place the whole blood sample on the Whatman On the card;

[0017] ② For standard / quality control samples, use a plastic pipette to mix blank whole blood and 5v / v% working solution of corresponding concentration, and apply to Whatman On the card;

[0018] ③For blank samples, use a plastic pipette to spot blank whole blood on the Whatman On the card;

[0019] Then they were dried at room temperature for 2-3 hours.

[0020] Furthermore, the concentration of the acetonitrile aqueous solution is 60 v / v%.

[0021] Furthermore, the preparation method of the internal standard working solution is: accurately weigh meropenem-d6, tigecycline-d9, and voriconazole-d3 standards, add a specified volume of 50v / v% methanol / water to dissolve, and obtain an internal standard mixed working solution of 0.16μg / ml meropenem-d6, 0.2μg / ml tigecycline-d9, and 0.0008μg / ml voriconazole-d3.

[0022] Furthermore, the ultrasonic time is 30 minutes.

[0023] Furthermore, the centrifugation parameters are: 14000g, 10min.

[0024] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:

[0025] The analysis method of the present invention adopts DBS technology, has a small amount of blood collection, and the sample is easy to store and transport. The biological hazard of the dried material is low and the sample stability is high.

[0026] The analytical method of the present invention has high sensitivity and can quantitatively detect the blood concentrations of 5 antibacterial drugs at the same time. It is applied to TDM research and pharmacokinetic research of critically ill patients. The blood sampling volume is only 30 microliters, which is friendly to frequent and multiple blood sampling of critically ill patients, and can provide technical support for clinical individualized treatment and PK / PD research. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The QC-LLOQ level chromatograms of meropenem in DBS samples; wherein, (A) blank DBS sample; (B) blank blood DBS sample with QC-LLOQ level analyte added; (C) blank blood DBS sample with internal standard (IS) added.

[0028] Figure 2 The QC-LLOQ level chromatograms of imipenem in DBS samples; wherein, (A) blank DBS sample; (B) blank blood DBS sample with QC-LLOQ level analyte added; (C) blank blood DBS sample with internal standard (IS) added.

[0029] Figure 3 The QC-LLOQ level chromatograms of tigecycline in DBS samples; wherein, (A) blank DBS sample; (B) blank blood DBS sample with QC-LLOQ level analyte added; (C) blank blood DBS sample with internal standard (IS) added.

[0030] Figure 4The QC-LLOQ level chromatograms of teicoplanin in DBS samples; wherein, (A) blank DBS sample; (B) blank blood DBS sample with QC-LLOQ level analyte added; (C) blank blood DBS sample with internal standard (IS) added.

[0031] Figure 5 The QC-LLOQ level chromatograms of vancomycin in DBS samples; wherein, (A) blank DBS sample; (B) blank blood DBS sample with QC-LLOQ level analyte added; (C) blank blood DBS sample with internal standard (IS) added. DETAILED DESCRIPTION

[0032] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but is not intended to be limiting of the present invention. It should be noted that the embodiments and features in the embodiments of the present invention may be combined with each other without conflict.

[0033] The chemicals and reagents used in the following examples include:

[0034] Meropenem trihydrate (batch number: C15621289), imipenem monohydrate (batch number: C15287449), and tigecycline (batch number: C15581884) were purchased from McLean (Shanghai, China). Meropenem-d6 (batch number: 20240105), tigecycline-d9 (batch number: 20240105), and voriconazole-d3 (batch number: 20230511) were purchased from Nanjing Pinsheng Medical Laboratory Co., Ltd. LC-MS grade acetonitrile, methanol, and formic acid were provided by Thermo Fisher Scientific (Shanghai) Co., Ltd. Purified water was purchased from Watsons Purified Water (Guangzhou) Co., Ltd. The reference standard met the ChP standard. Whatman Paper was purchased from Jundi Life Sciences (Shanghai) Co., Ltd.

[0035] Example 1

[0036] This example provides an analytical method for determining five antibacterial drugs, meropenem, imipenem, tigecycline, teicoplanin, and vancomycin, in dried blood spots by LC-MS / MS. The specific steps are as follows:

[0037] 1) Prepare standard solution

[0038] Mixed stock solution: Accurately weigh meropenem, imipenem, tigecycline, teicoplanin, and vancomycin standards, add the specified volume of 50 v / v% methanol / water to dissolve, and obtain a mixed stock solution with a meropenem concentration of 400 μg / mL, an imipenem concentration of 500 μg / mL, a tigecycline concentration of 16 μg / mL, a teicoplanin concentration of 1300 μg / mL, and a vancomycin concentration of 800 μg / mL.

[0039] Standard series working solution: Accurately weigh one portion of the mixed stock solution and dilute it with 50 v / v% methanol / water to prepare a standard series working solution.

[0040] Quality control working solution: Accurately weigh another portion of the mixed stock solution and dilute it with 50 v / v% methanol / water to prepare a quality control working solution.

[0041] Internal standard working solution: Accurately weigh meropenem-d6, tigecycline-d9, and voriconazole-d3 standards, add a specified volume of 50v / v% methanol / water to dissolve, and obtain an internal standard mixed working solution of 0.16μg / ml meropenem-d6, 0.2μg / ml tigecycline-d9, and 0.0008μg / ml voriconazole-d3.

[0042] 2) Prepare standard curve series samples and quality control samples

[0043] The standard series working solutions and quality control working solutions were diluted with blank human whole blood to obtain standard curve series samples and quality control samples, of which the concentrations of the five antimicrobial drugs are shown in Tables 1 and 2.

[0044] Table 1 Standard series working solutions

[0045]

[0046]

[0047] Table 2 Quality control working solution

[0048]

[0049] 3) Sample pretreatment (including whole blood samples, standard / quality control samples and blank samples)

[0050] The preparation method of DBS samples is as follows: ① For whole blood samples, use a disposable plastic pipette to spot 30 μL of whole blood sample on the Whatman ② For standard / quality control samples, add 190 μL blank whole blood to 10 μL working solution and mix evenly. Use a disposable plastic pipette to take 30 μL and apply it on the Whatman ③ For blank samples, use a disposable plastic pipette to spot 30 μL of blank whole blood on the Whatman Card; then all dried at room temperature (20-25°C) for 2 hours. When pre-treating DBS samples, the entire dried blood spot was cut from the DBS and transferred to an Eppendorf tube, and then 230 μL of 60 v / v% acetonitrile aqueous solution and 20 μL of internal standard working solution were added to the Eppendorf tube, ultrasonicated for 30 minutes, centrifuged (14000g, 10 minutes), and 100 μL of the supernatant was transferred to a 2mL glass HPLC bottle with a polypropylene insert.

[0051] 4) LC-MS / MS analysis was performed on a Thermo UltiMate 3000 ultra-high performance liquid chromatograph and a TSQ ENDURA triple quadrupole mass spectrometer.

[0052] The chromatographic column was Acquity UPLC BEH C18 (2.1×100mm, 1.7μm). The mobile phases included ultrapure water (mobile phase A) containing 0.1v / v% formic acid and acetonitrile (mobile phase B). The needle wash solution was 50% methanol-water. The column temperature was maintained at 45°C, and the injection volume was 2μL. The mobile phase flow rate was set to 0.3mL / min, and the total running time was 6 minutes. The gradient elution process was as follows: 0-1 minute, 0-30% B; 1-3 minutes, 30-98% B; 3-3.5 minutes, 98% B; 3.51-6 minutes, 1% B.

[0053] The mass spectrometer was operated in positive electrospray ionization mode with a spray voltage of 3500 V, an ion transfer tube temperature of 350 °C, a vaporization temperature of 400 °C, a sheath gas flow rate of 50, an auxiliary gas flow rate of 15, and a scan gas flow rate of 1. The MRM-related conditions (such as precursor ions, product ions, and collision energies) of antibiotics and internal standards (IS) are shown in Table 3 .

[0054] Table 3

[0055]

[0056] Example 2 Methodology Verification

[0057] 1. Selectivity

[0058] refer to Figure 1-5 The selectivity test showed that the responses of blank DBS from 5 different sources were all less than 20% of LLOQ and 5% of IS. There was no endogenous material interference between the analytes and the internal standard.

[0059] 2. Calibration Curve

[0060] The ratio of peak area to IS was used as the ordinate, and the specified concentrations of the five antibiotics were used as the abscissa, and fitted into a 1 / x2 weighted linear regression. Meropenem and tigecycline used meropenem-d6 and tigecycline-d9 as internal standards, respectively, and imipenem, ticlopenem and vancomycin hydrochloride used voriconazole-d3 as internal standard. The linear ranges of meropenem, imipenem, tigecycline, teicoplanin and vancomycin were 0.25-25μg / mL, 0.20-20μg / mL, 16-1600ng / mL, 0.65-65μg / mL, and 0.4-40μg / mL, respectively.

[0061] Table 4 Calibration curves of five antibiotics

[0062]

[0063] 3. Accuracy and precision

[0064] The accuracy of the meropenem QC-LLOD sample was 117.17%, and the accuracy of the tigecycline QC-LLOD sample was 16.7%, reaching the standard of within 20% of the nominal concentration. The accuracy of imipenem, teicoplanin, and vancomycin were all between 85% and 115%, and the precision was less than 15%. The intra-day and inter-day accuracy and precision data of the five antibiotics are shown in Table 5.

[0065] Table 5 Accuracy and precision results of five antibiotics in DBS

[0066]

[0067] 4. Matrix Effects and Recovery

[0068] The matrix effects of the five antibiotics at low and high concentrations for six different individuals fully met the test standards. The relative matrix effects were 86.5%-114.86%, and the CV (%) was less than 10.81%. Table 6 lists the recoveries of the five antibiotics at QC-L and QC-H concentration levels. The extraction recoveries of meropenem and imipenem were 71.01% to 78.24% and 48.73% to 46.51%, respectively.

[0069] Table 6 Matrix effects and recovery rates of five antibiotics in DBS (n=6)

[0070]

[0071] 5. Stability

[0072] The five antibiotics were highly stable in DBS, with no significant degradation in the autosampler for 12 hours, -20°C for 7 days, and -80°C for 30 days.

[0073] The above description is only a preferred embodiment of the present invention, and does not limit the implementation mode and protection scope of the present invention. For those skilled in the art, it should be aware that all solutions obtained by equivalent substitutions and obvious changes made using the contents of the specification and illustrations of the present invention should be included in the protection scope of the present invention.

Claims

1. An analytical method for determining five antibacterial drugs in dried blood spots by LC-MSMS, wherein the antibacterial drugs are meropenem, imipenem, tigecycline, teicoplanin and vancomycin, characterized in that: The steps include: Step 1, sample pretreatment; Step 2, using LC-MS / MS detection; The chromatographic conditions are: Chromatographic column: Acquity UPLC BEH C18, 2.1×100mm, 1.7μm; Mobile phase A: ultrapure water containing 0.1v / v% formic acid; Mobile phase B: acetonitrile; Column temperature: 45°C; Injection volume: 2μL; Mobile phase flow rate: 0.3mL / min; Total run time: 6 minutes; Gradient elution; The mass spectrometry conditions were: The ionization mode was positive electrospray ionization, the spray voltage was 3500 V, the ion transfer tube temperature was 350 °C, the vaporization temperature was 400 °C, the sheath gas flow rate was 50, the auxiliary gas flow rate was 15, and the scan gas flow rate was 1.

2. The analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS according to claim 1, characterized in that: The specific procedure of the gradient elution is: 0-1 min, 0-30% B; 1-3 min, 30-98% B; 3-3.5 min, 98% B; 3.51-min, 1% B.

3. The analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS according to claim 1, characterized in that: The specific steps of the sample pretreatment are: cutting the entire dried blood spot from the DBS sample and transferring it to an Eppendorf tube, adding acetonitrile aqueous solution and internal standard working solution, ultrasonicating, centrifuging, and obtaining a supernatant to be tested.

4. The analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS according to claim 3, characterized in that: The DBS sample is prepared as follows: ① For whole blood samples, use a plastic pipette to place the whole blood sample on the Whatman On the card; ② For standard / quality control samples, use a plastic pipette to mix blank whole blood with 5v / v% working solution of corresponding concentration and apply it to Whatman On the card; ③For blank samples, use a plastic pipette to spot blank whole blood on the Whatman On the card; Then they were dried at room temperature for 2-3 hours.

5. The analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS according to claim 3, characterized in that: The concentration of the acetonitrile aqueous solution is 60 v / v%.

6. The analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS according to claim 3, characterized in that: The preparation method of the internal standard working solution is: accurately weigh meropenem-d6, tigecycline-d9, and voriconazole-d3 standards, add a specified volume of 50v / v% methanol / water to dissolve, and obtain an internal standard mixed working solution of 0.16μg / ml meropenem-d6, 0.2μg / ml tigecycline-d9, and 0.0008μg / ml voriconazole-d3.

7. The analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS according to claim 3, characterized in that: The ultrasonic time is 30 minutes.

8. The analytical method for determining five antimicrobial drugs in dried blood spots by LC-MSMS according to claim 3, characterized in that: The centrifugal parameters are: 14000 g, 10 min.